NeOnc Technologies Holdings, Inc. Appoints Dr. Victoria Medvec to Board of Directors
NeOnc Technologies Holdings (upcoming NASDAQ: NTHI), a clinical-stage medical biotechnology company, has appointed Dr. Victoria Medvec to its Board of Directors. Dr. Medvec, CEO of Medvec and Associates and advisor to Fortune 100 companies, brings extensive experience in strategic partnerships, mergers and acquisitions, and regulatory negotiations.
Dr. Medvec currently holds the Adeline Barry Davee Professorship at Northwestern University's Kellogg School of Management and has advised major life sciences companies including Amgen, AstraZeneca, Bristol Myers Squibb, Gilead, Pfizer, and Sanofi. The appointment aims to strengthen NeOnc's position as it works toward commercializing central nervous system therapeutics and developing treatments for brain tumors.
NeOnc Technologies Holdings (prossimamente su NASDAQ: NTHI), una compagnia di biotecnologia medica in fase clinica, ha nominato Dr. Victoria Medvec nel suo Consiglio di Amministrazione. La Dr.ssa Medvec, CEO di Medvec and Associates e consulente per aziende Fortune 100, porta con sé un'ampia esperienza in partnership strategiche, fusioni e acquisizioni, e negoziazioni regolatorie.
Attualmente, la Dr.ssa Medvec detiene la Cattedra Adeline Barry Davee presso la Kellogg School of Management della Northwestern University e ha fornito consulenze a importanti aziende nel settore delle scienze della vita, tra cui Amgen, AstraZeneca, Bristol Myers Squibb, Gilead, Pfizer e Sanofi. La nomina mira a rafforzare la posizione di NeOnc mentre lavora per commercializzare terapie per il sistema nervoso centrale e sviluppare trattamenti per i tumori cerebrali.
NeOnc Technologies Holdings (próximamente en NASDAQ: NTHI), una empresa de biotecnología médica en etapa clínica, ha nombrado a la Dra. Victoria Medvec en su Junta Directiva. La Dra. Medvec, CEO de Medvec and Associates y asesora de empresas Fortune 100, aporta una amplia experiencia en asociaciones estratégicas, fusiones y adquisiciones, y negociaciones regulatorias.
Actualmente, la Dra. Medvec ocupa la Cátedra Adeline Barry Davee en la Kellogg School of Management de la Universidad Northwestern y ha asesorado a importantes empresas de ciencias de la vida, incluyendo Amgen, AstraZeneca, Bristol Myers Squibb, Gilead, Pfizer y Sanofi. La designación tiene como objetivo fortalecer la posición de NeOnc mientras trabaja para comercializar terapias para el sistema nervioso central y desarrollar tratamientos para tumores cerebrales.
NeOnc Technologies Holdings (곧 NASDAQ: NTHI 상장 예정), 임상 단계의 의료 생명공학 회사가 빅토리아 메드벡 박사를 이사회에 임명했습니다. 메드벡 박사는 Medvec and Associates의 CEO이자 Fortune 100 기업의 고문으로서 전략적 파트너십, 인수합병, 규제 협상 분야에서 폭넓은 경험을 가지고 있습니다.
현재 메드벡 박사는 Northwestern University의 Kellogg School of Management에서 Adeline Barry Davee 교수직을 맡고 있으며, Amgen, AstraZeneca, Bristol Myers Squibb, Gilead, Pfizer 및 Sanofi를 포함한 주요 생명 과학 기업에 자문을 제공해 왔습니다. 이번 임명은 NeOnc가 중추 신경계 치료제를 상용화하고 뇌 종양 치료제를 개발하는 과정에서의 입지를 강화하는 것을 목표로 하고 있습니다.
NeOnc Technologies Holdings (prochainement sur NASDAQ: NTHI), une entreprise de biotechnologie médicale en phase clinique, a nommé Dr. Victoria Medvec à son Conseil d'Administration. Le Dr Medvec, PDG de Medvec and Associates et conseillère pour des entreprises du Fortune 100, apporte une vaste expérience en partenariats stratégiques, fusions et acquisitions, ainsi qu'en négociations réglementaires.
Actuellement, le Dr Medvec occupe la chaire Adeline Barry Davee à la Kellogg School of Management de l'Université Northwestern et a conseillé de grandes entreprises des sciences de la vie, notamment Amgen, AstraZeneca, Bristol Myers Squibb, Gilead, Pfizer et Sanofi. La nomination vise à renforcer la position de NeOnc alors qu'elle travaille à la commercialisation de thérapies pour le système nerveux central et au développement de traitements pour les tumeurs cérébrales.
NeOnc Technologies Holdings (demnächst an der NASDAQ: NTHI), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat Dr. Victoria Medvec in seinen Vorstand berufen. Dr. Medvec, CEO von Medvec and Associates und Beraterin für Fortune 100 Unternehmen, bringt umfangreiche Erfahrung in strategischen Partnerschaften, Fusionen und Übernahmen sowie regulatorischen Verhandlungen mit.
Derzeit hält Dr. Medvec die Adeline Barry Davee Professur an der Kellogg School of Management der Northwestern University und hat bedeutende Unternehmen im Bereich der Lebenswissenschaften, darunter Amgen, AstraZeneca, Bristol Myers Squibb, Gilead, Pfizer und Sanofi, beraten. Die Ernennung zielt darauf ab, die Position von NeOnc zu stärken, während das Unternehmen daran arbeitet, Therapien für das zentrale Nervensystem zu kommerzialisieren und Behandlungen für Hirntumoren zu entwickeln.
- Strategic board appointment brings expertise in M&A and partnerships
- Addition of advisor with extensive Fortune 100 and pharmaceutical industry experience
- Strengthened corporate governance with experienced public and private board director
- Company still in clinical-stage with no commercialized products
- NASDAQ listing pending - not yet completed
Dr. Medvec adds extensive knowledge of high-stakes issues including mergers and acquisitions and partnerships to the NeOnc team
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol NTHI), a clinical-stage medical biotechnology company, announced today that Dr. Victoria Medvec, has been appointed to its Board of Directors. Dr. Medvec is the Chief Executive Officer of Medvec and Associates, a valued adviser to executives and boards at a substantial portion of Fortune 100 companies.
"We are thrilled to leverage Victoria's extensive experience in strategic partnerships, global market access, and regulatory negotiations,” said Dr. Thomas Chen, Chief Executive Officer of NeOnc. “She brings invaluable expertise on high-stakes issues including mergers and acquisitions, customer contracts, and supplier agreements, among others. Over her illustrious career, Victoria has advised prominent life sciences clients such as Amgen, AstraZeneca, Bristol Myers Squibb, Gilead, Pfizer, and Sanofi. Her presence on our Board enhances our potential for success, and will be invaluable as we work toward the successful commercialization of central nervous system therapeutics."
With a wealth of experience as a public and private board director, Dr. Medvec employs her expertise in negotiations and decision making to help companies drive revenue growth through optimization, risk management, corporate governance and mergers and acquisitions. Her research has been published in esteemed academic journals including Psychological Review and the Journal of Personality and Social Psychology. Additionally, she is the author of the best-selling book "Negotiate Without Fear."
"I am honored to join NeOnc's Board of Directors at such an exciting time," said Dr. Medvec. "I am passionate about the Company’s commitment to advancing innovative therapies for patients in need, and I look forward to working alongside a talented team to support NeOnc in achieving its mission to bring transformative solutions to patients living with debilitating brain tumors."
“Dr. Medvec’s strategic value to our company is significant,” said Amir Heshmatpour, NeOnc’s Executive Chairman. “We anticipate receiving significant benefits from her insights and guidance as NeOnc advances its infrastructure and clinical trials, while exploring potential partnerships within the biotech industry.”
Dr. Medvec holds the Adeline Barry Davee Professorship of Management and Organizations at Northwestern University’s Kellogg School of Management, where she has been a distinguished faculty member since 1995. She is the co-founder of the Kellogg Center for Executive Women. Her research has garnered attention from prestigious publications such as the Wall Street Journal, the New York Times, the Washington Post, and the Today Show.
Dr. Medvec earned her Bachelor of Arts degree from Bucknell University and obtained her Ph.D. in Psychology from Cornell University.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status.
The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonctech.com.
Important Cautions Regarding Forward Looking Statements
All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding our expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate," or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law.
“NEO100” is a registered trademark of NeOnc Technologies Holdings, Inc.
Company Contact:
Patrick Walters
Chief Operations Officer
NeOnc Technologies Holdings, Inc.
info@neonc.com
Investor Relations:
Roger Pondel / Laurie Berman
PondelWilkinson Inc.
(310) 279-5980
rpondel@pondel.com
lberman@pondel.com
FAQ
What strategic value does Dr. Victoria Medvec bring to NTHI's board?
What is NeOnc Technologies' (NTHI) current development focus?
When will NeOnc Technologies (NTHI) be listed on NASDAQ?
Which major pharmaceutical companies has Dr. Medvec previously advised?
